In conclusion, some imidazopyranotacrine derivatives showing selective modest AChE inhibition, whose pharmacokinetic parameters are within the acceptable range defined for human use, thereby indicating their potential as drug-like molecules and possible brain penetration, have been discovered for the potential treatment of AD. This evidence concerns the gene ACHE and Alzheimer disease.